{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:04:57Z","timestamp":1763705097193,"version":"3.37.3"},"reference-count":33,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Alkermes"},{"name":"Auspex"},{"DOI":"10.13039\/100007380","name":"Avenir","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007380","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009155","name":"Otsuka","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["K23MH098014"],"award-info":[{"award-number":["K23MH098014"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Psychiatric Association (Kempf Fund Award)"},{"DOI":"10.13039\/100008578","name":"Georgia Regents University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.schres.2015.10.001","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T15:44:17Z","timestamp":1445701457000},"page":"30-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3774-472X","authenticated-orcid":false,"given":"Neil","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2015.10.001_bb0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","author":"American Diabetes Association","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2015.10.001_bb0010","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.psyneuen.2012.04.001","article-title":"Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome","volume":"37","author":"Beumer","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2015.10.001_bb0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.psychres.2013.06.020","article-title":"Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia","volume":"210","author":"Boyer","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2015.10.001_bb0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2008.03.004","article-title":"Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives","volume":"103","author":"Carrizo","year":"2008","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2015.10.001_bb9000","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/HPC.0b013e318057d4c9","article-title":"Cardiovascular disease under the influence of excess visceral fat","volume":"6","author":"Despres","year":"2007","journal-title":"Clin. Pathways in Cardiol."},{"key":"10.1016\/j.schres.2015.10.001_bb0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11883-010-0098-3","article-title":"Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome","volume":"12","author":"Devaraj","year":"2010","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.schres.2015.10.001_bb0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"issue":"1\u20133","key":"10.1016\/j.schres.2015.10.001_bb0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2010.02.1028","article-title":"Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia","volume":"118","author":"Fan","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.10.001_bb0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.psychres.2011.05.010","article-title":"C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia","volume":"90","author":"Fawzi","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2015.10.001_bb0045","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.amjmed.2006.02.031","article-title":"Metabolic syndrome and risk of cardiovascular disease: a meta-analysis","volume":"119","author":"Galassi","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.schres.2015.10.001_bb0050","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2015.10.001_bb0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3346\/jkms.2008.23.2.193","article-title":"The associations of total and differential white blood cell counts with obesity, hypertension, dyslipidemia and glucose intolerance in a Korean population","volume":"23","author":"Kim","year":"2008","journal-title":"J. Korean Med. Sci."},{"issue":"3","key":"10.1016\/j.schres.2015.10.001_bb0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.psychres.2014.04.049","article-title":"Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine","volume":"218","author":"Klemettila","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2015.10.001_bb0065","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.atherosclerosis.2007.12.053","article-title":"White blood cell count and the metabolic syndrome in older Chinese: the Guangzhou Biobank Cohort Study","volume":"201","author":"Lao","year":"2008","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.schres.2015.10.001_bb0070","first-page":"214","article-title":"Metabolic syndrome and inflammation markers in patients with schizophrenia and recurrent depressive disorder","volume":"26","author":"Lasic","year":"2014","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.schres.2015.10.001_bb0075","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2015.10.001_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.10.001_bb0085","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antispychotic trials of intervention effectiveness study","volume":"66","author":"Meyer","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2015.10.001_bb0090","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effect","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2015.10.001_bb0095","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.biopsych.2012.09.007","article-title":"Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects","volume":"73","author":"Miller","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.10.001_bb0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbi.2012.08.016","article-title":"Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses","volume":"31","author":"Miller","year":"2013","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.schres.2015.10.001_bb0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3371\/CSRP.MICU.020813","article-title":"C-reactive protein levels in schizophrenia: a review and meta-analysis","volume":"7","author":"Miller","year":"2014","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.schres.2015.10.001_bb0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbi.2014.12.005","article-title":"Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses","volume":"45","author":"Miller","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2015.10.001_bb0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S003329171100105X","article-title":"Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices","volume":"42","author":"Mitchell","year":"2012","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.schres.2015.10.001_bb0120","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2015.10.001_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1751-7893.2012.00384.x","article-title":"Predictive utility of blood pressure, waist circumference and body mass index for metabolic syndrome in patients with schizophrenia in Singapore","volume":"7","author":"Nurjono","year":"2013","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.schres.2015.10.001_bb0130","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2169\/internalmedicine.50.5877","article-title":"Longitudinal study on white blood cell count and the incidence of metabolic syndrome","volume":"50","author":"Odagiri","year":"2011","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.schres.2015.10.001_bb0135","first-page":"51","article-title":"Association of erythrocyte sedimentation rate and fibroinogen concentration with metabolic syndrome in schizophrenic patients","volume":"25","author":"Pavlovic","year":"2013","journal-title":"Med. Acad. Mostariensia"},{"key":"10.1016\/j.schres.2015.10.001_bb0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2015.10.001_bb0145","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2015.10.001_bb0150","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2015.10.001_bb0155","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.2169\/internalmedicine.50.5908","article-title":"Significant correlation between visceral adiposity and high-sensitivity C-reactive protein (hs-CRP) in Japanese subjects","volume":"50","author":"Tsuriya","year":"2011","journal-title":"Intern. Med."},{"key":"10.1016\/j.schres.2015.10.001_bb0160","first-page":"275","article-title":"C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia","volume":"22","author":"Vuksan-Cusa","year":"2010","journal-title":"Psychiatr. Danub."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415300013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415300013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T01:47:32Z","timestamp":1569203252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996415300013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":33,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0920996415300013"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2015.10.001","relation":{},"ISSN":["0920-9964"],"issn-type":[{"type":"print","value":"0920-9964"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2015.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}